Introduction
Transforming growth factor-b (TGFb) is a secreted cytokine that regulates embryonic development and adult tissue homeostasis (Piek et al., 1999a) . TGFb binds to heteromeric complexes of type I (TbRI) and type II (TbRII) receptor serine/threonine kinases, which signal via cytoplasmic Smad proteins and alternative pathways, including mitogen-activated protein kinase (MAPK) and protein kinase B (PKB/Akt; Feng and Derynck, 2005; Moustakas and Heldin, 2005 ; Massagueá nd Gomis, 2006) . TGFb inhibits the proliferation of epithelial, endothelial and haematopoietic cells (Siegel and Massague´, 2003; Pardali and Moustakas, 2007) . On the other hand, TGFb can induce epithelial-mesenchymal transition (EMT), a term corresponding to multiple epithelial plasticity phenotypes, including transcriptional loss of E-cadherin and de novo expression of mesenchymal markers like vimentin and/or fibronectin (Gotzmann et al., 2002; Gru¨nert et al., 2003; Huber et al., 2005) . EMT is important during embryonic development and plays a role in human malignancy during tumour cell invasion and metastasis (Huber et al., 2005; Thiery and Sleeman, 2006; Pardali and Moustakas, 2007) .
Human tumours may acquire loss-of-function mutations in the receptor kinase and Smad genes, suggesting a tumour suppressive role of the TGFb pathway. However, loss of growth inhibition by TGFb is a common feature of tumour cells (Levy and Hill, 2006) , and most cancer cells secrete large amounts of TGFb (Dalal et al., 1993; Ivanovic et al., 1995; Shim et al., 1999) . This promotes tumour progression as proven in studies of tumour cell lines and mouse models (Pardali and Moustakas, 2007) . In vivo, TGFb induces EMT of carcinoma cells and induces cytokine-mediated crosstalk with the tumour stroma, promoting tumour cell invasiveness and metastatic potential (Huber et al., 2005) .
In some cellular cancer models, EMT and metastasis required cooperation of TGFb with activated oncogenes such as H-Ras or activated receptor tyrosine kinases (Gru¨nert et al., 2003; Huber et al., 2005) . In the EpRas model, for instance, complete, metastable EMT requires 5-7 days of TGFb stimulation in collagen gels (threedimensional (3D) cultures)-shorter TGFb treatment causing partial, reversible EMT (Jechlinger et al., 2006; Waerner et al., 2006) -but is strongly impaired on plastic dishes (Gotzmann et al., 2002; Gru¨nert et al., 2003; Huber et al., 2005) . In the murine mammary epithelial cell line namru murine mammary gland (NmuMG)-a commonly used in vitro model of TGFb-induced EMThowever, short-term TGFb treatment (24-48 h) causes cell cycle arrest and reversible EMT in the absence of oncogene cooperation, accompanied by apoptosis in the majority of cells (Jechlinger et al., 2006; Waerner et al., 2006) . In this model, the effect of sustained TGFb treatment on EMT, proliferation and survival has not yet been addressed.
In this report, we analysed the responses of NMuMG cells to both acute (24-96 h) and chronic exposure (up to 2-3 weeks) to TGFb. The latter treatment gave rise to actively proliferating cells (transdifferentiated (TD) cells), which largely had undergone EMT. This TD phenotype represented an essentially reversible epithelial plasticity change, characterized by co-suppression of antiproliferative, proapoptotic (Smads, p38 kinase) and proliferation/survival enhancing, EMT-inducing signalling pathways (MAPK, PI3K-Akt) to low levels. Importantly, an in vivo tumour microenvironment rich in secreted TGFb stimulated the non-tumorigenic NMuMG cells to contribute to tumours in mice, enhancing the growth rate of the tumour cells and therefore tumour mass by secretion of mitogenic chemokines. Thus, chronic exposure to TGFb may downmodulate its own signalling in a manner allowing TGFb-resistant proliferation and survival, as well as induction of reversible EMT, all of which are essential but not sufficient steps during malignant tumour progression.
Results
TGFb-induced EMT of NMuMG cells in 2D and 3D cell culture models NMuMG cells were exposed to TGFb1 for 24-120 h, both on plastic and in 3D collagen matrices. After 24 h, cells acquired a more fibroblastoid cell shape, but still formed distinct islands. After 48-120 h, an increasing proportion of cells (>30%) disintegrated (data not shown), whereas the surviving cells showed an increasingly strong fibroblastoid phenotype (Figure 1a) . Marker analysis after 48 h showed strong suppression of the epithelial markers E-cadherin and ZO-1 (Figure 1b) . Before EMT, the mesenchymal marker fibronectin was cytoplasmatically expressed at low levels, but strongly upregulated upon EMT induction by TGFb1, localized both extracellularly and to the cytoplasm (Figure 1b) . Furthermore, the actin cytoskeleton changed from a cortical arrangement to that of stress fibres (Piek et al., 1999b) . Finally, the EMT markers vimentin and N-cadherin-expressed before and after EMT-changed from diffuse cytoplasmic (vimentin) or plasma membrane localization (N-cadherin) to a fibrillar, intracellular distribution (data not shown).
In 3D collagen gels, NMuMG formed compact, sometimes tubular structures within 7 days. In response to TGFb1 (96 h), these structures changed to unordered, branched strands or cords consisting of fibroblastoid, spindle-like cells, together with significant cell disintegration ( Figure 1c ). E-cadherin was dramatically reduced, whereas fibronectin was strongly upregulated (Figure 1c) , and actin localization switched from cortical rings to stress fibres (data not shown).
Chronic TGFb exposure of NMuMG cells causes resistance to TGFb-induced proliferation arrest and promotes cell migration and EMT For chronic TGFb treatment, NMuMG cells were exposed to TGFb1 for up to 3 weeks, mimicking an in vivo tumour microenvironment often rich in secreted TGFb (Oft et al., 1996) . During the first 24-48 h, TGFb1 strongly suppressed proliferation of NMuMG cells (Figure 2a ), followed by partial apoptosis indicated by elevated levels of cleaved caspase-3, a major effector of apoptosis ( Figure 2b) . A total of 15-20 days after TGFb exposure, the surviving cells resumed full proliferation, and continued to grow as stable, variant cell lines (referred to as TD, transdifferentiated, cells). These cells were no longer proliferation-arrested by TGFb1 (Figure 2a ), which also failed to cause cell disintegration and to elevate activated caspase-3 from low, basal levels, as typical for TGFb-treated NMuMG control cells (Figure 2b ). Finally, TD cells could transmigrate through porous substrates much more effectively than parental NMuMG cells (Figure 2c ), correlating with their fibroblastoid morphology in both two-dimensional (2D) and 3D cultures (Figures 3a and b) .
Analysis of EMT markers in 2D culture revealed that E-cadherin was downregulated in TD cells (except some small E-cadherin-positive clusters) as well as ZO-1, whereas fibronectin was strongly enhanced and extracellularly deposited (Figure 3a) . In 3D culture assays, TD cells formed unordered, branched structures containing reduced E-cadherin and clearly enhanced fibronectin expression (Figure 3b) . Importantly, EMT of TD cells in 2D and 3D culture was fully reversed by a specific inhibitor of TbRI (Ex0050005) showing similar morphology and marker expression patterns as control NMuMG cells (Figures 3a and b; Figure 1 ). This indicates that TD cells, generated by chronic TGFb treatment, show metastable but fully reversible EMT characterized by partial loss of E-cadherin but complete bypass of antiproliferative and apoptotic TGFb responses.
The sustained EMT of TD cells is reversed upon TGFb removal
We next addressed whether the EMT phenotype of TD cells could be reversed upon plain removal of TGFb. TD Sustained TGFb signalling favours EMT A Gal et al The kinetics of EMT marker expression were analysed by immunoblot analysis of TD cells during TGFb withdrawal and restimulation. E-cadherin was fully regained already after 2 days (TD2À), whereas loss of fibronectin was only complete after 6 and 12 days (TD6À, TD12À). Acute restimulation with TGFb1 gradually reduced E-cadherin levels and restored fibronectin expression (Figure 5b ). In addition, TD cells exhibited low levels of the transcriptional regulator Id2-a well established inhibitor of EMT (Kowanetz et al., 2004) -and TGFb could not further decrease such low Id2 protein levels. In TD2À, TD6À and TD12À cells, Id2 was re-expressed to levels similar or exceeding those in control NMuMG cells, and was again repressed by TGFb1 restimulation (Figure 5b ). Thus, EMT of TD cells is completely reversible by both TbRI inhibitors and plain TGFb withdrawal.
Resistance of TD cells to TGFb-induced growth inhibition is partially reversible
We then analysed whether the resistance of TD cells to TGFb-induced proliferation arrest and apoptosis was also reversible upon TGFb withdrawal. This treatment partially restored TGFb-induced proliferation arrest, causing a 2.5-fold reduction in thymidine incorporation, as compared with a >10-fold reduction in control NMuMG cells (Figure 6a ). Determination of activated (cleaved) caspase-3 during TGFb1 withdrawal showed, that cleaved caspase-3 was strongly induced after 2 days, and superinduced by TGFb1 re-addition, whereas control TD cells showed low, TGFb-insensitive levels. Interestingly, cleaved caspase-3 levels declined again upon more prolonged withdrawal of TGFb1 (TD6À and TD12À cells) and became insensitive to restimulation with TGFb1 ( Figure 6b ). These results indicate that TGFb-mediated proliferation arrest and apoptosis are partially or transiently reversible in TD cells, respectively.
Chronic TGFb exposure affects Smad-dependent and -independent signalling pathways To get some mechanistic insight into how the TD cell phenotype is generated, we first analysed TGFb receptor-induced, Smad-dependent signalling, known to induce cell cycle arrest and apoptosis. TGFb-induced transcriptional activity mediated by Smad3 and Smad4 was determined in reporter assays, employing an adenovirally expressed, synthetic promoter/reporter construct CAGA 9 -luciferase (Dooley et al., 2001) . Control NMuMG cells exhibited a strong, lasting response to TGFb1 treatment (24 and 48 h), whereas TD cells showed hardly any TGFb-induced transcriptional activation (Figure 7a ). TGFb1 withdrawal of TD cells for 2 days was sufficient to restore a strong, but transient CAGA 9 response, whereas a more lasting Sustained TGFb signalling favours EMT A Gal et al response required 6 days of factor withdrawal ( Figure 7b) . Similarly, TGFb-induced Smad2 phosphorylation, as determined in immunoblots, was strongly suppressed in TD cells, both before and after restimulation with fresh factor. Importantly, phospho-Smad2 levels were rapidly restored upon factor withdrawal within 6-24 h (Figure 7c ), and even after 12 days (data not shown), resembling those in NMuMG control cells upon acute TGFb1 stimulation.
Using TD cells before and after TGFb withdrawal and re-stimulation, we also examined three major Smadindependent TGFb-signalling pathways (Gru¨nert et Parental NMuMG cells expressed considerable levels of the proliferation-promoting, antiapoptotic signal transducers phospho-PKB/Akt and phospho-ERK and the antiproliferative signalling intermediate phospho-p38 (Huber et al., 2005; Hui et al., 2007) , all of which were further elevated by TGFb1 (Figure 7d) . In TD cells, however, all three signal transducers showed strongly reduced, TGFb-insensitive phosphorylation levels. Whereas Smad-2/3/4-dependent signalling recovered within 12-48 h (see above), 2-6 and 6-12 days of TGFb1 withdrawal were required to restore TGFb-inducible phospho-p38 and phospho-ERK/phospho-PKB/Akt, respectively, to levels similar as in NMuMG control Figures 3 and 4 , see Supplementary Materials), exposed or not exposed (control) to 0.3 mM Ex0050005 for 4 days. Shown are the brightfield micrographs and confocal images of TD cells stained for E-cadherin and fibronectin. Nuclei, DAPI (blue). Bars are as follows: phase-contrast and brightfield micrographs, 50 mm; confocal images, 20 mm. In respective NMuMG controls, Ex0050005 did not affect morphology and EMT marker expression (data not shown). 2D, two-dimensional; EMT, epithelial-mesenchymal transition; TD, transdifferentiated.
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A Gal et al cells (Figure 7d ). Interestingly, TD cells withdrawn from TGFb1 for 12 days showed high levels of phospho-Akt regardless of the presence or absence of TGFb1, using two different assays (Figure 7d and Supplementary  Figure 1) . In summary, chronic TGFb exposure of NMuMG cells reversibly suppresses both antiproliferative, proapoptotic pathways (Smads, p38-kinase), and those stimulating proliferation, survival and EMT (PI3K-Akt, MAPK/Erk) to low but significant levels.
NMuMG cells chronically exposed to TGFb in vivo contribute to CHO tumour formation by enhancing tumour cell proliferation To expose NMuMG cells to conditions of chronic TGFb stimulation in vivo, male severe combined immunodeficient mice were co-injected subcutaneously with NMuMG cells plus tumorigenic Chinese Hamster ovary (CHO) cells or CHO cells stably expressing ectopic TGFb1 (CHO-TGFb1). CHO cells rapidly gave rise to tumours (Figures 8a and b) , in which no TGFb was detected (data not shown). Co-injected NMuMG cells were undetectable in CHO tumours and tumour development remained unaffected (Figures 8a and b) . In contrast, CHO-TGFb1 cells formed slow-growing, vimentin-positive and E-cadherin-negative tumours, which strongly secreted TGFb (Figure 8c ). Co-injection of NMuMG and CHO-TGFb1 cells gave rise to often multilayered, E-cadherin-positive and vimentin-negative epithelioid structures within the tumours (Figure 8c ). These were of NMuMG origin, as demonstrated by DNA-fluorescent in situ hybridization analysis (Supplementary Figure 2) . These mixed tumours À1 TGFb1) or after TGFb1 withdrawal for 2, 6 and 12 days (TD2À, TD6À, TD12À). Collagen gels were either left untreated (control, that is, no additional TGFb1) or restimulated with 1 ng ml À1 TGFb1 for 96 h. Bars, 50 mm. TD, transdifferentiated; TGFb1, transforming growth factor-b1.
showed a statistically significant enhancement of both tumour growth rate and final tumour mass (Figures 8a and b) .
The mixed NMuMG/CHO-TGFb1 tumours did not contain sufficient NMuMG-derived, epithelial structures to easily explain their strongly increased growth rate and final mass. Analysis of the mixed NMuMG/ CHO-TGFb1 tumours showed no change in apoptosis (Figure 9a ), whereas the CHO-TGFb1 tumour cells proliferated significantly more compared with the tumours derived from CHO-TGFb1 cells alone (Figures  9b and c) . In conclusion, chronic TGFb stimulation of NMuMG cells in the mixed tumours allowed their proliferation and survival, and enhanced proliferation of the CHO-TGFb1 tumour cells, thus increasing tumour growth.
To analyse how NMuMG cells enhanced proliferation of CHO-TGFb1 cells within the mixed tumours, cultured NMuMG, TD and CHO-TGFb1 cells were analysed for secretion of multiple mitogenic factors, including chemokines. NMuMG cells secreted the chemokines JE/MCP-1, LIX and KC, whereas TD cells maintained JE/MCP-1 secretion but produced reduced levels of LIX and KC. In contrast, CHOTGFb1 cells failed to secrete detectable levels of these chemokines (Figure 9d) . Accordingly, recombinant JE/MCP-1 (100 ng ml À1 ) caused a statistically significant enhancement of CHO-TGFb1 cell proliferation (Figure 9e ). At higher concentrations (300-400 ng ml À1 ), LIX and KC also increased CHO-TGFb1 cell proliferation, but never to the same level as JE/MCP-1 (data not shown). Thus, NMuMG cells chronically exposed to TGFb in vivo may be induced to secrete chemokines, which enhance proliferation of CHO-TGFb1 tumour cells. 
A Gal et al
Discussion
Cellular mechanisms responsible for the dual functionality of TGFb as a tumour suppressor and an inducer of EMT and metastasis during carcinoma progression are a major topic of current research (Roberts and Wakefield, 2003; Pardali and Moustakas, 2007) . In this paper, we addressed the phenotypic and signalling responses of murine mammary epithelial NMuMG cells to chronic TGFb stimulation. This induced a new, epithelial plasticity phenotype in NMuMG cells, in which suppression of antiproliferative and proapoptotic TGFb signalling (Smads, p38 kinase) might allow similarly low, constitutive levels of the PI3K-Akt and MAPK pathways to cause reversible EMT and resistance to TGFb-mediated proliferation inhibition and apoptosis (Janda et al., 2002a) . Exposure of non-tumorigenic NMuMG cells to a TGFb-rich tumour environment in mixed NMuMG/CHO-TGFb1 tumours induced them to form adenoma-like, NMuMG-derived structures that enhanced proliferation of CHO-TGFb1 tumour cells, probably via secreted chemokines. 
Sustained TGFb signalling favours EMT A Gal et al
EMT and protection from TGFb-mediated cell cycle arrest and apoptosis in TD cells is not due to irreversible, epigenetic or genetic changes The TD cell phenotype includes reversible EMT and protection from TGFb-induced cell cycle inhibition and apoptosis (Figures 2 and 3) . The following evidence supports our idea that this TD cell phenotype is generated by reversible epithelial plasticity changes rather than irreversible, random genetic or epigenetic alterations. First, the EMT of TD cells was completely reversible upon treatment with both TbRI kinase inhibitors and withdrawal of TGFb for 6-12 days (Figures 3-5) . Second, both Smad-dependent and -independent signalling pathways were reversibly suppressed to low, but significant levels in TD cells and regained TGFb responsiveness as in control NMuMG cells within 12-48 h (Smad) or 6-12 days (p38 kinase and MAPK/Erk; Figure 7 ) after TGFb withdrawal. Third, the low levels of the phospho-inositide-3-kinase (PI3K) target PKB/Akt in TD cells were likewise elevated 6 and 12 days after factor withdrawal, but remained high thereafter, both in the absence and presence of TGFb. Since hyperactivation of the PI3K-PKB/Akt pathway stimulates both proliferation and survival (Janda et al., 2002b; Jechlinger et al., 2006) , this might explain, why TGFb-induced resistance to proliferation inhibition was only partially restored in TD cells, even 10-15 days after factor deprivation ( Figure 6 , and data not shown). Similarly, activated caspase-3 was transiently elevated 2 days after TGFb withdrawal (Figure 6 ), when phosphoAkt levels were still low (Figure 7 ), but suppressed again later, when phospho-Akt levels were elevated. We cannot exclude genetic/epigenetic events causing this high, constitutive PI3K signalling, but observed that the PI3K inhibitor LY 294002 fully restored TGFb-induced proliferation inhibition and apoptosis of TD12À populations in 3D culture (data not shown). Together with the fact that several independently generated TD12À cell populations behaved identically in these experiments, we consider it unlikely, that the elevated, constitutive PI3K-Akt activity in TD12À cells is due to random, epigenetic or genetic alterations.
TD cells show an epithelial plasticity phenotype distinct from EMT induced by cooperation of TGFb with oncogenes The oncogene-free TD cells show some interesting differences to cell systems that induce EMT via oncogene (for example, Ha-Ras) overexpression and TGFb signalling. First, Ras-transformed EpH4 cells (EpRas cells) show metastable EMT due to an autocrine TGFb loop, and this phenotype is not fully reversed by 
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TGFb withdrawal or TbRI inhibitors (Oft et al., 1996) . In contrast, EMT of TD cells is fully reversed by both treatments (Figures 3-5) . Second, probably due to its reversible nature, EMT in TD cells shows minor differences in EMT marker expression as compared with EpRas cells in both 2D and 3D culture (Figures  3-5; Janda et al., 2002a) . Third, in EpRas cells, both hyperactivated PI3K and extracellular signal-regulated kinase (ERK) signalling, and inhibition of Smaddependent TGFb signalling are dependent on oncogenic Ras (Oft et al., 1996) . In contrast, TD cells show oncogene-independent alterations in signalling, that is, suppression of phosphorylation/activation of Smads and p38 kinase, which both inhibit proliferation and/or or KC at 100 ng ml À1 for 96 h and subjected to the WST-1 proliferation assay. Asterisks indicate data statistically significant (JE, Po0.0001; LIX, Po0.05). TD, transdifferentiated; TGFb1, transforming growth factor-b1.
A Gal et al survival ( Figure 7 ; Huber et al., 2005; Hui et al., 2007) . Under these conditions, the low level of PI3K and MAPK/ERK pathway activity observed in TD cells may be sufficient to induce EMT, proliferation and survival. This hypothetic mechanism might more closely correspond to loss of TGFb sensitivity in human carcinoma cells, which only rarely show overexpression of mutated Ras.
In vivo relevance of alterations caused in NMuMG cells by chronic TGFb exposure Direct analysis of the relevance of the TD cell phenotype with respect to tumour formation in vivo was difficult, since NMuMG cells are non-tumorigenic in severe combined immunodeficient mice, whereas both NMuMG and TD cells failed to contribute to tumours induced by co-injected CHO cells. However, chronic exposure of NMuMG cells to a TGFb-rich tumour microenvironment-mixed tumours of NMuMG cells and TGFb1-secreting CHO-TGFb1 cells-allowed NMuMG cells to form benign, adenoma-like, E-cadherin-positive and vimentin-negative structures within these tumours (Figure 8 ). Since NMuMG cells survived and proliferated in CHO-TGFb1, but not in CHO tumours, it is possible that the TGFb-rich microenvironment in NMuMG/ CHO-TGFb1 mixed tumours induced a TD cell-like phenotype in vivo. Interestingly, these co-injected NMuMG cells strongly enhanced both proliferation of CHO-TGFb1 cells and final tumour mass.
In cell culture, NMuMG and TD cells secreted chemokines (for example, JE/MCP-1) at levels, which enhanced proliferation of CHO-TGFb1 cells (Figures 9d  and e) , suggesting a similar process contributing to tumour growth rate in vivo. Since chemokines and their receptors are difficult or impossible to detect by immunohistochemistry (IHC) due to diffusion and/or extremely low expression levels, we did not try to confirm these cell culture data in tumours. TGFb induces multiple growth factors and chemokines in transformed epithelial cells (Balkwill, 2004; Jechlinger et al., 2006; Waerner et al., 2006) , for example, platelet-derived growth factor (PDGF) and interleukin-like EMT inducer (ILEI), which are both essential for metastasis, while ILEI induces multiple chemokines (Jechlinger et al., 2006; Waerner et al., 2006) .
In contrast to TD cells in culture, NMuMG cells in NMuMG/CHO-TGFb1 mixed tumours did not undergo EMT, but frequently formed multilayered hyperplastic structures expressing E-cadherin but not vimentin (Figure 8c ). Since TD cells showed a weaker EMT phenotype in culture (E-cadherin-positive islands), differing from both NMuMG and TD12À cells after TGFb exposure, it is possible that the epithelioid, hyperplastic structures in the mixed tumours represent the in vivo counterpart of the TD cell phenotype in 3D culture. In addition, the ECM-bound TGFb might act differently on NMuMG cells in vivo than TGFb1 employed in culture.
In summary, we provided in vitro and in vivo support to our idea that chronic exposure of NMuMG cells to TGFb uniquely modulates their own phenotypical and signalling responses to this factor, enabling them to survive, proliferate and undergo EMT or local invasion.
Materials and methods

Cells and cell culture
Murine mammary epithelial NMuMG cells, freshly obtained from American Type Culture Collection (ATCC; Manassas, VA, USA), were cultured in Dulbecco's Modified Eagle's medium plus 10% foetal bovine serum, 10 mg ml À1 insulin, 100 U ml À1 penicillin and 50 mg ml À1 streptomycin. TD cells were generated by serial passaging at E90% confluency in the above medium, plus 5 ng ml À1 TGFb1 for up to 3 weeks. For TGFb withdrawal, TD cells were washed, trypsinized, plated in new dishes and maintained in medium without TGFb1 for 2, 6 or 12 days (TD2À, TD6À, TD12À cells, respectively), passaging them again when necessary. Cell aliquots were restimulated with 5 ng ml À1 TGFb1, added to the medium for 48 h. To measure signal transducer protein phosphorylation (Figures 7c and d 
Adenoviral infections and gene reporter assays
Adenoviruses expressing b-galactosidase (Adex-lac-z) and CAGA 9 -MLP-luc (Adeasy-CAGA 9 -MLP-luc) (kind gifts from K Miyazono, Tokyo, Japan, and S Dooley, Aachen, Germany, respectively), were used for cell infection and gene reporter assays as detailed in Supplementary Material.
Transmigration assay
A total of 2.5 Â 10 4 cells were plated in 24-well transmigration chambers (353182; BD and Co., Franklin Lakes, NJ, USA) in 0.5 ml Dulbecco's Modified Eagle's medium supplemented with 0.1% bovine serum albumin and 20 mg ml À1 transferrin. As chemoattractant, 5% foetal bovine serum medium was added into the lower wells, 750 ml well
À1
. For details, see Supplementary Materials.
Immunoblotting
For total cell lysates, cells were lysed on ice in kinase buffer (20 mM Tris.HCl, pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 2 mM ethylenediaminetetraacetic acid , 20 mM NaF, 1 mM b-glycero-phosphate, 1 mM Na 3 VO 4 and Complete inhibitor cocktail from Roche Diagnostics Wien GmbH, Vienna, Austria). Cleared protein lysates (25-30 mg) were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis and electroblotted on polyvinylidene difluoride membranes. Proteins were detected using the appropriate primary antibodies (Supplementary Materials), and respective secondary antibodies plus ECL on Hyperfilm ECL (GE Healthcare, Uppsala, Sweden).
ELISA
Secreted JE/MCP-1, KC and LIX chemokines were assayed at appropriate dilutions after harvesting supernatants from confluent cell cultures (24 h incubation), using Quantikine enzyme-linked immunosorbant assay (ELISA) kits for JE/ MCP-1 and KC, and DuoSet MouseLIX for LIX measurements (MJE00, MKC00B, DY443, respectively; R&D Systems Inc.) according to the manufacturer's instructions. Chemokine concentrations were normalized to cell numbers counted after supernatant removal.
Immunofluorescence of cells grown on porous supports (2D culture) Cells cultivated on porous supports were fixed at 70-80% confluency and processed for immunofluorescence as described earlier (Janda et al., 2002a) . For minor modifications and details, see Supplementary Materials.
Immunofluorescence of 3D collagen cultures
Three-dimensional cultures of NMuMG cells and derivatives in collagen gels were generated, phase-contrast micrographs taken and immunofluorescence analysis performed as described (Janda et al., 2002a) . For details/modifications, see Supplementary Materials.
In vivo tumour growth assays
The animal work in this study was approved by the Uppsala board of animal experimentation, and was carried out in accordance with the United Kingdom Coordinating Committee on Cancer Research (UKCCCR) guidelines. For details, see Supplementary Materials.
Immunohistochemistry
Tumour sections were processed as described (Sjo¨blom et al., 2001) . For details of immunohistochemistry, see Supplementary Materials.
